採用
必須スキル
Go
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.
We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.
GRAIL is headquartered in the bay area of California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
For more information, please visit grail.com
This is a great opportunity to join the growing commercial team at GRAIL, as a GRAIL Galleri Consultant (GGC1), working hand in hand with sales leadership and internal stakeholders to execute the go to market sales strategy for GRAIL’s revolutionary MCED (multi-cancer early detection) product Galleri. https://www.galleri.com/
This is a customer-focused position that requires a “market builder” mindset. A successful GGC1 acts with urgency and passion to engage physicians and their staff to think differently about cancer screening and change the way they practice, integrating MCED technology into their office workflow, and consistently offering it to appropriate patients with the goal to identify more cancers sooner.
GRAIL is the first company in the world to bring MCED technology to patients and clinicians - this is a rare opportunity in one's career!
The GGC1 role is an in-person selling role, with the expectation that candidates spend the majority of their time (>85%) making in-person visits to targeted physician practices, planning and supporting events, and executing on Company initiatives.
This is a field-based role located in your city and state, currently covering the following territory: Cincinnatti, Dayton and Northern KY and surrounding areas. While you will primarily operate in the field, travel to a GRAIL office or other locations may be required to support business needs.
We’re building a world-class team to take on one of healthcare’s most important challenges. Are you ready to join us?
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
類似の求人

DT Bill Of Material Functional/Technical Analyst
Raytheon (RTX) · US-CT-REMOTE

Production Assistant-Warner Theatre
Live Nation · Washington, DC, USA

Northern California Stagehand (Non-Union)
Live Nation · 4 Locations

Contracts Administrator - Level 2
Northrop Grumman · United States-California-Redondo Beach

Client Relationship Consultant 2 (Banker) Muscatine (Sign-On Bonus $1,500)
US Bancorp · Muscatine, IA
Grailについて

Grail
Series CGRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
201-500
従業員数
Menlo Park
本社所在地
$3.2B
企業価値
レビュー
3.9
10件のレビュー
ワークライフバランス
3.8
報酬
3.5
企業文化
4.2
キャリア
3.0
経営陣
3.2
72%
友人に勧める
良い点
Good work-life balance
Supportive team and management
Innovative and challenging projects
改善点
Heavy workload and overwhelming at times
Limited career advancement opportunities
Management and communication issues
給与レンジ
135件のデータ
Junior/L3
Mid/L4
Senior/L5
Director
Junior/L3 · Operations Engineer 2
1件のレポート
$103,500
年収総額
基本給
$90,000
ストック
-
ボーナス
-
$103,500
$103,500
面接体験
4件の面接
難易度
2.8
/ 5
期間
14-28週間
体験
ポジティブ 25%
普通 75%
ネガティブ 0%
面接プロセス
1
Application Review
2
Recruiter Screen
3
Technical Phone Screen
4
Onsite/Virtual Interviews
5
Team Matching
6
Offer
よくある質問
Technical Knowledge
Behavioral/STAR
Past Experience
Coding/Algorithm
ニュース&話題
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy - Stock Titan
Stock Titan
News
·
6d ago
My Grail Everyday Watch Gets the Perfect Summer Revamp - Gear Patrol
Gear Patrol
News
·
6d ago
Lilly's $2.25B bet chases genetic medicine's 'holy grail' - FirstWord Pharma
FirstWord Pharma
News
·
6d ago
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
BioSpace
News
·
6d ago